|Mr. Reginald L. Hardy M.B.A., R.Ph.||Co-Founder & Chairman||74k||N/A||1958|
|Attorney Robert Busard Brown||CEO & Director||711k||N/A||1962|
|Mr. Andrew D. Sklawer||Co-Founder, COO & Sec.||492.5k||N/A||1985|
|Mr. Deepak Chadha||Chief R&D Officer||479.83k||N/A||1970|
|Mr. Albert Nicholas Marchio II||Chief Financial Officer||N/A||N/A||1952|
|Mr. Jose Breton||Controller & Chief Accounting Officer||N/A||N/A||1989|
|Mr. David R. Mcavoy J.D.||Gen. Counsel & Chief Compliance Officer||N/A||N/A||1963|
|Mr. Gary S. Walker||Chief Marketing Officer||N/A||N/A||1960|
|Ms. Sue Fattor||Head of Human Resource||N/A||N/A||N/A|
|Ms. Nancy Seretta||VP & Head of Clinical Operations||N/A||N/A||N/A|
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Brickell Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.